CIP
BNR

Champlain Investment Partners’s Burning Rock Biotech BNR Stock Holding History

Champlain Investment Partners’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,834
Closed -$270K – 143
2021
Q4 		$270K Sell
2,834
-190
-6% -$26K ﹤0.01% 143
2021
Q3 		$541K Buy
3,024
+14
+0.5% +$3.11K ﹤0.01% 140
2021
Q2 		$887K Buy
+3,010
New +$891K ﹤0.01% 136

Other funds holding BNR

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Champlain Investment Partners's BNR Position: Q1 2022 in Review

Champlain Investment Partners sold out of Burning Rock Biotech (BNR) in Q1 2022, closing a stake of 2,834 shares — an estimated $270K sold.

Champlain Investment Partners first reported a position in BNR in Q2 2021 and held it in 3 quarters. The position peaked at $887K in Q2 2021. 46 funds tracked by Wall St. Rank hold BNR as of Q1 2022.

  • Champlain Investment Partners reported no remaining Burning Rock Biotech position as of Q1 2022 after selling out during the quarter.
  • Champlain Investment Partners sold 2,834 Burning Rock Biotech shares in Q1 2022, an estimated $270K.
  • Champlain Investment Partners first reported a position in Burning Rock Biotech in Q2 2021 and held it in 3 quarters.
  • Champlain Investment Partners's Burning Rock Biotech position peaked at $887K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q1 2022.

Based on Champlain Investment Partners's 13F filing for Q1 2022, filed 12 May 2022.